Cell and gene therapy

#Cell and gene therapy #Cell therapy #Gene therapy #RNA

Webinar on the advancements driving cell and gene therapies

In this webinar on 8 October 3-4PM BST, hosted by DDW and sponsored by Benchling, you will learn about the challenges and advancements driving drug development for cell and gene therapies. You will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and… Read More

Webinar date:
Sponsored by Benchling
#News

Myeloma
#CAR-T #Cell and gene therapy #Cell therapy #FDA #Myeloma #Poseida Therapeutics #Roche

‘Off-the-shelf’ CAR-T secures FDA advanced therapy designation

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Roche and Poseida Therapeutics’ P-BCMA-ALLO1. P-BCMA-ALLO1 is an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase I/Ib clinical development for the treatment of patients with relapsed/refractory multiple myeloma. The… Read More

#News #Regulatory

Cell and gene therapy concept
#Cell and gene therapy #Cell therapy #Gene therapy #RNA

What are the advancements driving CGT drug development?

In this webinar on 8 October 3-4PM BST, hosted by DDW and sponsored by Benchling, you will learn about the challenges and advancements driving drug development for cell and gene therapies. You will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and… Read More

Webinar date:
Sponsored by Benchling
#News

Gene therapy concept
#Cell and gene therapy #Cell manufacturing #Cell therapy #Gene therapy

Looking ahead for cell and gene therapy

DDW’s Megan Thomas discusses the future of the cell and gene therapy (CGT) sector with industry experts, who predict what to expect in 2024 and beyond. Emphasis on manufacturing  Experts were unanimous in their view of how far the cell & gene therapy (CGT) sector has come and the milestones… Read More

#Exclusive Content

CAR-T cell therapy
#CAR-T #Cell and gene therapy #Cell therapy #Lymphoma #Oncology

The curative potential of CAR-T cell therapy

Dr Nicholas Siciliano, Co-Founder of Vittoria Biotherapeutics, shares insight on the VIPER-101 trial targeting T-cell lymphoma, the company’s aim to ensure progression free survival and opportunities in this sector.  MT: I understand that your lead programme is moving into the clinic, with POC human data expected in 2024. Can you… Read More

#Cancer Research #Exclusive Content

Collagen and vitamin drop skin cell
#Ageing #Cell and gene therapy #Gene therapy #Rejuvenation therapies

Using gene therapy to live longer, healthier lives

Sharon Rosenzweig-Lipson, PhD, is Chief Scientific Officer of Life Biosciences. She discusses with DDW’s Megan Thomas the company’s lead programme; a gene therapy called ER-100. Prolonging health span with drug development Life Biosciences aims to restore and prolong a patient’s health span by targeting the underlying biology of ageing and… Read More

#Exclusive Content

CAR-T therapy
#CAR-T #Caring Cross #Cell and gene therapy #Collaboration #GermFree #Manufacturing

Collaboration plans to democratise cell and gene therapies

Modular cleanroom company GermFree and non-profit Caring Cross have announced a new partnership, hoping to make cellular gene therapies more available to patients. The companies plan to create a decentralised, point-of-care manufacturing model that combines GermFree’s mobile cleanroom units with Caring Cross’s manufacturing technologies and pipeline… Read More

#News

Cell and gene therapy concept
#AAV #Cell and gene therapy #Gene delivery #Gene therapy #Viral vectors

Improving viral vector safety for gene therapies

Dr Andrea O'Hara, Senior Product Manager at Azenta Life Sciences asks why integration site analysis (ISA) is critical for the safety and efficacy of viral vectors for gene therapy. Cell and gene therapies have revolutionised how clinicians treat a variety of diseases including cancer, blindness, and metabolic disorders. With these… Read More

#Exclusive Content

#Cell and gene therapy #Cell therapy #Gene therapy

Reflecting on the past and present of CGT development

DDW Multimedia Editor Megan Thomas speaks to industry experts to reflect on where the industry and has come over the last year, gain an understanding of what to expect from the 2024 cell & gene therapy (CGT) sector, and where future opportunities may lie. Workforce development and training Bruce Levine,… Read More

#Exclusive Content

Drug discovery innovation
#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Immunology / Virology & Vaccines #Interview #Life sciences #Market reporting #Precision medicine #RNA #RNA sequencing #Scandinavia #Sweden #Transcriptomics

Podcast: Innovation drivers and opportunities for drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovation drivers and opportunities for drug discovery”, which covers three articles written Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Optimising AAV capsid purification through improved analytics How… Read More

#News

Human brain
#Cell and gene therapy #Cell therapy #Gene therapy #Neurodegenerative disorders #Neuroscience

Five cell and gene therapy advances in neurodegeneration

Neurodegenerative diseases have recently increased at an alarming rate due to the ageing global population. There are a number of cell and gene therapies (CGTs) currently being developed to address these increasingly prevalent conditions. Diana Spencer provides an overview. A neurorestorative treatment Asklepios BioPharmaceutical’s (AskBio’s) AB-1005 is an adeno-associated virus… Read More

#Exclusive Content

#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

New eBook: Creating opportunities from advanced therapies

Cell and gene therapies (CGTs) are the fastest growing area of therapeutics, with many preclinical and clinical programmes currently underway. While cancer is key target for CGTs, these advanced therapies are also under investigation to treat conditions as varied as asthma, multiple sclerosis, ophthalmological conditions like… Read More

#News

DDW Cell and gene therapy eBook
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

Cell & gene therapy: Creating opportunities from advanced therapies

This eBook explores the current challenges and opportunities in the cell and gene therapy (CGT) space, and the factors likely to influence this area of therapeutics in the future. Download this exclusive eBook to learn more about: How innovative approaches are taking CGTs from bench to bedside The importance of… Read More

#DDW eBooks #Intelligence

#Advanced Therapies #Advanced Therapy Medicinal Products (ATMPs) #CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Guide #Market reporting

Podcast: The global innovation and the opportunity in CGTs

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers five articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: The promise and growth of cell and gene therapies… Read More

#News

Tumour microenvironment
#Cell and gene therapy #Cell therapy #Interview #Oncology #T cell receptor (TCR)

Unlocking T-cell receptor therapy for cancer

Keir Loiacono, CEO of BlueSphere Bio, discusses the goals of the company’s lead programme, the opportunities and potential of T-cell receptor (TCR) T cell therapies, and how to make oncology therapies tailored to individuals a reality. The goals of TCX-101 BlueSphere’s lead programme, TCX-101, includes two goals. The first is… Read More

#Cancer Research #Exclusive Content

Human adenovirus
#AAV #Cell and gene therapy #Cell and Gene Therapy Catapult #Collaboration #Gene delivery

Cross-industry consortium to improve AAV formulation

The Cell and Gene Therapy Catapult (CGT Catapult) has established a cross-industry consortium to improve the understanding and process optimisation of adeno-associated virus (AAV) formulation. AAV-based gene therapies are being developed to treat a broad range of inherited and chronic diseases and several of these therapies have already… Read More

#News